Latest Breaking News On - Junctional epidermolysis bullosa - Page 1 : vimarsana.com

Almirall, S A : Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases

Almirall, S A : Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Comunidad autonoma de catalunaJohn woolfordStefan klotterSumit aggarwalKarl ziegelbauerLaureen cassidyEloxx pharmaceuticals incEloxx pharmaceuticalsCorporate communicationsSpanish stock exchangeDystrophic epidermolysis bullosaJunctional epidermolysis bullosaChief executive officerChief scientific officerRibosome modulating agentsEukaryotic ribosome selective glycosides

Almirall and Eloxx Pharmaceuticals Enter into Exclusive

Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and other diseases associated with.

Comunidad autonoma de catalunaSumit aggarwalKarl ziegelbauerSpanish stock exchangeEloxx pharmaceuticals incEloxx pharmaceuticalsDystrophic epidermolysis bullosaJunctional epidermolysis bullosaChief executive officerChief scientific officerRibosome modulating agentsEukaryotic ribosome selective glycosidesPrivate securities litigation reform actNasdaq capital marketQuarterly report

FDA Approves Birch Triterpenes Topical Gel for Epidermolysis Bullosa

The FDA’s approval of Chiesi Global Rare Diseases’ topical gel marks the first approval for the variant of EB known as JEB.

United statesGiacomo chiesiBrett kopelanDrug administrationChiesi global rare diseasesJunctional epidermolysis bullosaDystrophic epidermolysis bullosaButterfly diseaseButterfly diseaseEpidermolysis bullosaBirch triterpenesTopical gel

Chiesi Global Rare Diseases Receives FDA Approval for FILSUVEZ® (birch triterpenes) topical gel for the Treatment of Epidermolysis Bullosa

Chiesi Global Rare Diseases Receives FDA Approval for FILSUVEZ® (birch triterpenes) topical gel for the Treatment of Epidermolysis Bullosa
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomChiesi groupchiesiAmryt pharmaStriar lifesci communicationsemailGiacomo chiesiBrett kopelanEuropean commissionAmryt pharmaceuticalsChiesi groupB corpChiesi group media contactchiara travaginrare communication managertelAlessio pappagallopress office managertelDrug administrationDystrophic epidermolysis bullosaGlobal rare diseases

Chiesi Global Rare Diseases Receives FDA Approval for FILSUVEZ® (birch triterpenes) topical gel for the Treatment of Epidermolysis Bullosa

Chiesi Global Rare Diseases Receives FDA Approval for FILSUVEZ® (birch triterpenes) topical gel for the Treatment of Epidermolysis Bullosa
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomBrett kopelanAlessio pappagalloGiacomo chiesiChiara travaginAmryt pharmaLifesci communicationsB corpAmryt pharmaceuticalsChiesi groupDrug administrationEuropean commissionChiesi group media contactDystrophic epidermolysis bullosaGlobal rare diseases